All inspectors · Key sources (PDF) · Antithrombotics sheet (PDF)
The Antithrombotic Therapy Around PCI one-pagerOpen it in a new tab

The patient in front of you

Mrs. K., 77, with hypertension, presented with 5 hours of chest pain at rest, ST depression in V2–V4 and a rising troponin. Angiography the next day showed a single 90% stenosis of the proximal left anterior descending artery, treated with a drug-eluting stent by radial access. She was loaded with aspirin and ticagrelor. She has never bled and takes no anticoagulant; eGFR 48, hemoglobin 12.6 g/dL, platelets 214, ejection fraction 55%, sinus rhythm. It is now day 2 and she is ready to go home.

This page helps you decide: She is high bleeding risk by two minor ARC-HBR criteria — can dual therapy stop at 1 month?

After this page you can

Your routine for every trial

Work through the six steps in order. Each question at the end belongs to one step, and the answer is on that step's page.

  1. Who was studied? Which patients could enter, which could not, and how sick were they?
  2. Compared with what? What did one group get that the other did not, and what was measured?
  3. What was the main result? Both percentages, the effect size with its 95% CI, and the number needed to treat (and to harm).
  4. Any design traps? Blinding, the choice of endpoint, how close the CI comes to no effect, how long it took, who paid.
  5. Does it apply to my patient? Would my patient have been allowed into the trial?
  6. What did it change? What the guideline now says, and what the trial does not tell you.

Take-home

For Mrs. K. (high bleeding risk by two minor criteria), MASTER DAPT supports a plan made at discharge, not a stop: dual therapy for one month, then, if that month is uneventful, stopping one drug and continuing a single antiplatelet agent, which avoids about one clinically relevant bleed for every 35 patients, with ischemic events non-inferior. In her course, atrial fibrillation appears at week 3, before that visit, and the WOEST page takes over. On the one-pager it sits on page 2, in the “Shorter DAPT — what the trials showed” box (high-bleeding-risk row), beside the ARC-HBR table.